The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release

British Journal of Pharmacology

Volumn 157, Issue 4, 2009, Pages 633-644

  Ong, W K ^a   Gribble, F M ^b   Reimann, F ^b   Lynch, M J ^c   Houslay, M D ^c   Baillie, G S ^c   Furman, B L ^a   Pyne, N J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CAMP; Dominant negative; Glucagon like peptide 1; GLUTag cells; H89; PDE4D4; Phosphodiesterase; Rolipram

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; GLUCAGON LIKE PEPTIDE 1; ROLIPRAM; CYCLIC AMP; GLUCOSE; ISOENZYME; ISOQUINOLINE DERIVATIVE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PDE4D PROTEIN, RAT; PHOSPHODIESTERASE III; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ANIMAL EXPERIMENT; ARTICLE; CATALYST; CELL CLONE; CELL LINE; CONTROLLED STUDY; DRUG INHIBITION; EXPERIMENTAL RAT; IN VITRO STUDY; IN VIVO STUDY; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENTEROENDOCRINE CELL; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; SECRETION;

ANIMALS; CELL LINE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; ENTEROENDOCRINE CELLS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; ISOENZYMES; ISOQUINOLINES; MICE; PROTEIN KINASE INHIBITORS; RATS; ROLIPRAM; SULFONAMIDES;

EID: 70349898505     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00194.x     Document Type: Article

References (46)

1. Ahmad M, Abdel-Wahab Y, Tate R, Flatt P, Pyne N, Furman B (2000). Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11. Br J Pharmacol 129: 1228-1234. (Pubitemid 30153980)
2. Baillie G, Sood A, McPhee I, Gall I, Perry S, Lefkowitz R et al. (2003). beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100: 940-945.
3. Beavo JA, Brunton LL (2002). Cyclic nucleotide research - still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718.
4. Bolger G, Erdogan S, Jones R, Loughney K, Scotland G, Hoffmann R et al. (1997). Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328 (Pt 2): 539-548. (Pubitemid 27515598)
5. Bolger G, McCahill A, Huston E, Cheung Y, McSorley T, Baillie G et al. (2003). The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 278: 49230-49238.
6. Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A et al. (2006). Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J 398: 23-36. (Pubitemid 44231298)
7. Brubaker PL, Schloos J, Drucker DJ (1998). Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139: 4108-4114. (Pubitemid 28513695)
8. Cantin L, Magnuson S, Gunn D, Barucci N, Breuhaus M, Bullock W et al. (2007). PDE-10A inhibitors as insulin secretagogues. Bioorg Med Chem Lett 17: 2869-2873.
9. Chu Z, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A et al. (2008). A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149: 2038-2047. (Pubitemid 351574507)
10. Conti M, Beavo JJ (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-1451
11. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003). Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278: 5493-5496. (Pubitemid 36800786)
12. Damholt A, Buchan A, Kofod H (1998). Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology 139: 2085-2091. (Pubitemid 28513872)
13. Degerman E, Manganiello V, Hoist JJ, Ahrén B (2004). Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. Eur J Pharmacol 498: 319-323. (Pubitemid 39208095)
14. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL (1994). Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol 8: 1646-1655.
15. Egan J, Meneilly G, Habener J, Elahi D (2002). Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. / Clin Endocrinol Metab 87: 3768-3773. (Pubitemid 34879525)
16. Flint A, Raben A, Astrup A, Holst JJ (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520. (Pubitemid 28084232)
17. Furman B, Pyne N (2006). Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus. Curr Opin Investig Drugs 7: 898-905. (Pubitemid 44613717)
18. Gribble FM, Williams L, Simpson AK, Reimann F (2003). A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52: 1147-1154. (Pubitemid 36523349)
19. Härndahl L, Jing X, Ivarsson R, Degerman E, Ahrén B, Manganiello V et al. (2002). Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of Insulin. J Biol Chem 277: 37446-37455.
20. Härndahl L, Wierup N, Enerbäck S, Mulder H, Manganiello V, Sundler F et al. (2004). Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology. J Biol Chem 279: 15214-15222. (Pubitemid 38618917)
21. Holz GG, Habener JF (1992). Signal transduction crosstalk in the endocrine system: pancreatic beta-cells and the glucose competence concept. Trends Biochem Sci 17: 388-393.
22. Houslay MD, Adams DR (2003). PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18.
23. Houslay MD, Baillie GS, Maurice DH (2007). cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100: 950-966.
24. Huang Z, Ducharme Y, Macdonald D, Robichaud A (2001). The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5: 432-438.
25. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
26. Islam D, Zhang N, Wang P, Li H, Brubaker PL, Gaisano H et al. (2009). Epac is involved in cAMP-stimulated proglucagon expression and hormone production, but not hormone secretion in pancreatic alpha and intestinal L cell lines. Am J Physiol Endocrinol Metab 296: E174-E181.
27. Koyanagi M, Suga H, Hoshiyama D, Ono K, Iwabe N, Kuma K et al. (1998). Ancient gene duplication and domain shuffling in the animal cyclic nucleotide phosphodiesterase family. FEBS Lett 436: 323-328. (Pubitemid 28482954)
28. Liu H, Maurice DH (1998). Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic. AMP Br J Pharmacol 125: 1501-1510. (Pubitemid 28548563)
29. Lotfi S, Li Z, Sun J, Zuo Y, Lam P, Kang Y et al. (2006). Role of the exchange protein directly activated by cyclic adenosine 5′-monophosphate (Epac) pathway in regulating proglucagon gene expression in intestinal endocrine L cells. Endocrinology 147: 3727-3736. (Pubitemid 44079377)
30. Lugnier C (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
31. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E et al. (2005). RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280: 33178-33189. (Pubitemid 41397113)
32. McCahill A, McSorely T, Huston E, Hill EV, Lynch MJ, Gall I et al. (2005). In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAPtethered protein kinase A type II located in the centrosomal region. Cell Signal 17: 1158-1173. (Pubitemid 40933535)
33. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R et al. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-E988.
34. Overton HA, Fyfe MC, Reynet C (2008). GPR119, a novel G proteincoupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153 (Suppl. 1): S76-S81. (Pubitemid 351340991)
35. Pyne N, Furman B (2003). Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 46: 1179-1189. (Pubitemid 37214975)
36. Reimann F, Gribble FM (2002). Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes 51: 2757-2763.
37. Reimann F, Ward PS, Gribble FM (2006). Signalling mechanisms underlying the release of glucagon-like peptide 1. Diabetes 55: S78-S85. (Pubitemid 44927036)
38. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM (2008). Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539.
39. Reimer R, Darimont C, Gremlich S, Nicolas-Métral V, Rüegg U, Macé K (2001). A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 142: 4522-4528.
40. Semple G, Fioravanti B, Pereira G, Calderón I, Uy J, Choi K et al. (2008). Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 51: 5172-5175.
41. Shafiee-Nick R, Pyne NJ, Furman B (1995). Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity. Br J Pharmacol 115:1486-1492.
42. Simpson A, Ward P, Wong K, Collord G, Habib A, Reimann F et al. (2007). Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia 50: 2181-2189. (Pubitemid 47373843)
43. Thompson WJ, Appleman MM (1971). Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10: 311-316.
44. Walz H, Wierup N, Vikman J, Manganiello V, Degerman E, Eliasson L et al. (2007). Beta-cell PDE3B regulates Ca2+-stimulated exocytosis of insulin. Cell Signal 19: 1505-1513.
45. Yarwood S, Steele M, Scotland G, Houslay M, Bolger G (1999). The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274: 14909-14917. (Pubitemid 129518822)
46. Zhao A, Zhao H, Teague J, Fujimoto W, Beavo J (1997). Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94: 3223-3228. (Pubitemid 27157292)